Non Hodgkin Lymphoma Articles & Analysis: Older
20 news found
Each case is represented by duplicate nuclear cores, providing ample material for analysis. In addition, the Non-Hodgkin’s Lymphoma Tissue Microarray 4, 80 Cases, 42 Cores (Catalog NO. IMCT038) is a microarray focused on non-Hodgkin’s lymphoma tissues that can be applied in IHC, ISH ...
Darolutamide, which is jointly developed by Bayer and Orion Corporation, is an oral androgen receptor inhibitor indicated for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease and for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). ...
ByBayer AG
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of ...
This complements the currently ongoing CD19 Phase1/2 programs in recurring/refractory Non-Hodgkin Lymphoma (rrNHL; ATALANTA study) and recurring/refractory Chronic Lymphocytic Leukemia (rrCLL; EUPLAGIA study). ...
The PRAC recommendations will now be considered by the Committee for Medicinal Products for Human Use (CHMP) for an opinion Abstract accepted for poster presentation at the Annual Society of Hematology (ASH) conference taking place 10-13 December 2022 on the initial data from the ATALANTA-1 Phase 1/2 study in recurring/refractory Non-Hodgkin ...
Ansell, MD, PhD, Professor of Medicine, Division of Hematology at the Mayo Clinic, with extensive expertise in B-cell malignancies, including both Hodgkin and non-Hodgkin lymphomas Todd A. Fehniger, MD, PhD, Professor of Medicine, Washington University School of Medicine, an internationally recognized leader in natural killer ...
AVM Biotechnology, LLC, a clinical stage company advancing AVM0703 in the treatment of Non-Hodgkin’s Lymphoma (NHL)/Leukemia, today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. ...
These strategic additions to the leadership team are timed with the near completion of the safety portion of a pivotal clinical trial in treating “no-option” Non-Hodgkin’s Lymphoma/Leukemia patients. The safety dose-escalation portion of the study is projected to be completed in Q1-Q2 2022 with the efficacy portion, already ...
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell ...
(Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced positive interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet’s investigational therapy targeting CD20 for the potential treatment of B-cell ...
(Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company will host a webcast presentation on Monday, December 6, 2021 at 8:30 AM EST to discuss interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet’s ...
Kheiron Medical Technologies today announced its new collaboration with researchers at Stanford University to design functional proof-of-concept deep learning models to solve clinical problems in novel ways, starting with Non-Hodgkin’s Lymphoma (NHL). With the collaboration, Kheiron, which has pioneered the development and deployment of ...
Sharman pioneered the use of B-cell receptor antagonists and has since led numerous studies contributing to the development and regulatory approval of BTK and PI3K inhibitors in chronic lymphocytic leukemia and Non-Hodgkin’s lymphoma. Beyond these therapeutic classes, Dr. ...
AVM Biotechnology, a clinical-stage company, announced today FDA permission to modify its ongoing clinical study, AVM0703-001, entitled “The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma”. The initial protocol, a 3 x 3-based design, called for dose escalation of 3 mg/kg for each of the six cohorts, ranging from 6 mg/kg to 21 mg/kg, with a minimum of three ...
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut ...
ByEnterome
AVM Biotechnology is excited to advance AVM0703 to the next dose level cohort of no-option lymphoma patients. The drug has been well tolerated, without safety issues, as expected. ...
Additionally, a second approved trial with AVM0703 in Non-Hodgkin’s Lymphoma will be enrolling patients shortly. AVM Biotechnology also has an active Expanded Access (“Compassionate Use”) Program for AVM0703 (https://avmbiotech.com/compassionate-use/), and template documents and guidance for treating physicians to facilitate ...
The previously approved study will evaluate AVM0703 in refractory/relapsed Non-Hodgkin’s Lymphoma patients. This second study consists of two different ARDS patient populations: one with COVID-19- mediated moderate to severe ARDS and the other with Influenza-mediated severe ARDS. ...
Additionally, hematologists now call for optimized, multigene platform analysis that includes FLT3 mutations.1 Thermo Fisher plans to introduce additional hematology-oncology clinical research assays for B-cell and T-cell clonality and somatic hypermutation assessment through immune repertoire sequencing to study lymphoid malignancies, including chronic lymphocytic leukemia (CLL), acute ...
The researchers also noted that diseases such as non-Hodgkin's lymphoma, hepatocellular and prostate carcinoma, and Alzheimer's disease have been associated with the common chemicals metabolized by GSTP1. ...